Valuation: Clene Inc.

Market Cap 61.12M 53.76M 50.83M 46.11M 86.59M 5.87B 87.09M 609M 235M 2.99B 229M 225M 9.62B P/E 2026 *
-1.67x
P/E 2027 * -2.52x
Enterprise Value 56.52M 49.71M 47.01M 42.64M 80.07M 5.43B 80.54M 563M 217M 2.77B 212M 208M 8.9B EV / Sales 2026 *
227x
EV / Sales 2027 * 2.7x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-3.95%
1 week-8.81%
Current month-3.27%
1 month-2.13%
3 months-34.65%
6 months-14.11%
Current year-29.47%
1 week 4.01
Extreme 4.01
4.7
1 month 3.25
Extreme 3.25
4.7
Current year 3.25
Extreme 3.25
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
159.59
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 2013-03-31
Chief Tech/Sci/R&D Officer 67 2012-12-31
Director of Finance/CFO 57 2022-01-31
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 53 2019-08-31
Director/Board Member 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Free

Chief Executive Officer

15,244 0.1186%
9/16/26 Free

Chairman

434,451 3.3813%
9/16/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-4.19%-8.81%-30.88%-58.60% 61.12M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+38.19%+86.90% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
+0.81%-2.42%-16.65%+358.35% 25.73B
+0.79%+1.07%+0.97%-2.92% 24.75B
+1.10%+1.86%+25.66%-7.59% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.11%+1.71%+43.46%+159.94% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.52%-0.24%+29.85%+143.30% 27.52B
Weighted average by Cap. -0.03%-1.05%+37.70%+126.21%

Financials

2026 *2027 *
Net sales 249K 219K 207K 188K 353K 23.94M 355K 2.48M 959K 12.22M 936K 916K 39.26M 23.27M 20.46M 19.35M 17.55M 32.96M 2.23B 33.15M 232M 89.48M 1.14B 87.35M 85.46M 3.66B
Net income -34.49M -30.33M -28.68M -26.02M -48.86M -3.31B -49.14M -343M -133M -1.69B -129M -127M -5.43B -31M -27.26M -25.78M -23.38M -43.91M -2.98B -44.17M -309M -119M -1.52B -116M -114M -4.88B
Net Debt -4.6M -4.05M -3.83M -3.47M -6.52M -442M -6.55M -45.81M -17.69M -225M -17.27M -16.9M -724M 1.8M 1.58M 1.5M 1.36M 2.55M 173M 2.56M 17.92M 6.92M 88.17M 6.76M 6.61M 283M
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
26-09-28 US$4.120 -4.19% 54,760
26-09-25 US$4.300 +2.14% 136,464
26-09-24 US$4.210 -1.86% 47,751
26-09-23 US$4.290 -2.05% 75,250
26-09-22 US$4.380 -3.52% 135,773
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.300USD
Average target price
32.20USD
Spread / Average Target
+648.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock